4/27
06:40 am
fbio
India's Sun Pharma Plots $12 Billion Organon Buyout For Global Reach [Yahoo! Finance Canada]
Low
Report
India's Sun Pharma Plots $12 Billion Organon Buyout For Global Reach [Yahoo! Finance Canada]
4/27
05:03 am
fbio
Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy Organon In Deal Valued At $11.8 Billion [Forbes]
Low
Report
Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy Organon In Deal Valued At $11.8 Billion [Forbes]
3/31
04:05 pm
fbio
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
High
Report
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
3/30
04:20 pm
fbio
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
Medium
Report
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
3/30
04:05 pm
fbio
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
High
Report
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
3/19
06:20 am
fbio
Fortress Biotech (FBIO) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Fortress Biotech (FBIO) was downgraded by Zacks Research from "strong-buy" to "hold".
2/25
08:38 pm
fbio
Fortress Biotech's Cyprium enters agreement to sell PRV for $205M [Yahoo! Finance]
Low
Report
Fortress Biotech's Cyprium enters agreement to sell PRV for $205M [Yahoo! Finance]
2/23
11:23 am
fbio
Fortress Biotech (NASDAQ:FBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Medium
Report
Fortress Biotech (NASDAQ:FBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
2/23
09:55 am
fbio
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
High
Report
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
2/23
09:24 am
fbio
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
High
Report
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2/23
08:48 am
fbio
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
High
Report
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
2/23
08:30 am
fbio
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Medium
Report
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2/23
08:00 am
fbio
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Low
Report
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease